Researchers at the University of Eastern Finland have identified the SMVT transporter protein that can improve creatine delivery to the brain and potentially enable new therapies targeting the central nervous system. The discovery addresses one of medicine's greatest challenges: delivering drugs across the blood-brain barrier.
Biotechnology startup creator Flagship Pioneering is combining three of its portfolio companies—Etiome, Cellarity, and Empress Therapeutics—into a new venture called Etcelera. The merged company will use artificial intelligence and drug discovery tools to predict which experimental medicines might succeed in clinical trials.
A large-scale multi-ancestry genetic study led by Ole Andreassen at University of Oslo has identified new DNA risk factors for Alzheimer's disease, implicating microglial and neuronal dysregulation. The research reveals a larger common-variant contribution to the disease than previously estimated and identifies potential new drug targets.
Researchers have developed RPT04402, a molecular glue that stabilizes protein phosphatase 2A (PP2A), a key regulator of cell signaling pathways frequently disrupted in tumors. The compound shows promise in inhibiting non-small cell lung cancer and uterine cancer development.
OpenAI has acquired Orchestra Bio, a startup building AI agents to help pharmaceutical companies manage drug development. The acquisition signals OpenAI's expansion into the healthcare sector, following rival Anthropic's similar moves.
Swiss drugmaker Roche has entered a partnership with Atavistik Bio potentially worth nearly $2 billion, including milestone payments, to develop oral treatments for cardiovascular, kidney and metabolic diseases. The deal includes $70 million upfront with an additional $1.9 billion in potential milestone payments.
Insilico Medicine announced that rentosertib, an experimental lung disease drug developed using artificial intelligence, demonstrated the ability to reduce biological age markers in a 42-patient trial. Six independently built aging clocks all showed patients on the drug appeared biologically younger, according to a study conducted with researchers from Harvard Medical School, Stanford University, and The Broad Institute.
Rentosertib, an experimental lung disease drug developed using artificial intelligence, demonstrated the ability to reverse biological signs of aging in a study, according to its developer, suggesting broader potential applications beyond its original target condition.
Michael Polansky's biotech startup Outer Biosciences has emerged from stealth after four years, revealing technology that keeps surgically discarded human skin tissue alive for up to a month outside the body. The company trains AI models on how the living tissue reacts to compounds to discover new skincare treatments.
Boulevard Bio emerged from stealth with $65 million in funding from Deerfield Management, co-founded by renowned autoimmune researcher Georg Schett and former Sanofi CSO Frank Nestle. The startup is advancing three antibody programs targeting autoimmune diseases, with its lead candidate BLVD101 in early clinical development for IgA nephropathy.
Researchers at the University of Utah Health have used artificial intelligence and genetic analysis to identify molecular signals and drug candidates that could modify osteoarthritis disease progression, moving beyond current symptom-management approaches. The research includes insights into purinergic signaling pathways that influence joint inflammation and cartilage degeneration.